Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II Study of BL-B01D1 for Injection in Recurrent Glioblastoma
CTR20243484Phase 2Active
- Sponsor
- Biokin Pharmaceutical
- Start
- Oct 2024
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of izalontamab brengitecan in glioblastoma (GBM), sponsored by Biokin Pharmaceutical. Started Oct 2024; status: active.
02
Drugs
izalontamab brengitecan
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on CTR20243484.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20243484.